Sign in →

Test ID MOGFS Myelin Oligodendrocyte Glycoprotein (MOG-IgG1) Fluorescence-Activated Cell Sorting (FACS) Assay, Serum


Specimen Required


Patient Preparation: For optimal antibody detection, specimen collection should occur prior to initiation of immunosuppressant medication.

Collection Container/Tube:

Preferred: Red top

Acceptable: Serum gel

Submission Container/Tube: Plastic vial

Specimen Volume: 2 mL

Collection Instructions: Centrifuge and aliquot serum into a plastic vial.


Forms

If not ordering electronically, complete, print, and send 1 of the following with the specimen:

-Neurology Specialty Testing Client Test Request (T732)

-General Request (T239)

Secondary ID

65563

Useful For

Diagnosis of inflammatory demyelinating diseases (IDD) with similar phenotype to neuromyelitis optica (NMO) spectrum disorder (NMOSD), including optic neuritis (single or bilateral) and transverse myelitis

 

Diagnosis of autoimmune myelin oligodendrocyte glycoprotein (MOG)-opathy

 

Diagnosis of NMO

 

Distinguishing NMOSD, acute disseminated encephalomyelitis (ADEM), optic neuritis, and transverse myelitis from multiple sclerosis early in the course of disease

 

Diagnosis of ADEM

 

Prediction of a relapsing disease course

Reflex Tests

Test ID Reporting Name Available Separately Always Performed
MOGTS MOG FACS Titer, S No No

Testing Algorithm

When the results of this assay require further evaluation, the reflex titer test will be performed at an additional charge.

Method Name

Flow Cytometry

Reporting Name

MOG FACS, S

Specimen Type

Serum

Specimen Minimum Volume

1 mL

Specimen Stability Information

Specimen Type Temperature Time Special Container
Serum Refrigerated (preferred) 28 days
  Frozen  28 days
  Ambient  72 hours

Reject Due To

Gross hemolysis Reject
Gross lipemia Reject
Gross icterus Reject

Reference Values

Negative

Day(s) Performed

Monday, Tuesday, Thursday

Report Available

5 to 8 days

Performing Laboratory

Mayo Clinic Laboratories in Rochester

Test Classification

This test was developed and its performance characteristics determined by Mayo Clinic in a manner consistent with CLIA requirements. It has not been cleared or approved by the US Food and Drug Administration.

CPT Code Information

86363

86363-titer (if appropriate)